Assessing pricing and affordability of HBV treatment in Asia–Pacific region: a barrier to elimination
Despite patent expiration and availability of low-cost generics for TDF and ETV, HBV medication costs in Asia-Pacific region remain high. CHB treatment is generally unaffordable for patients, posing a significant barrier to HBV elimination in this endemic region.
Authors
- Saeed Hamid (ORCID: https://orcid.org/0000-0001-7218-6885)
- Jin Mo Yang (ORCID: https://orcid.org/0000-0002-8339-4716)
- Shiv Kumar Sarin (ORCID: https://orcid.org/0000-0002-0544-5610)
- Masao Omata (ORCID: https://orcid.org/0000-0001-7977-1497)
- Jidong Jia (ORCID: https://orcid.org/0000-0002-9407-8890)
- Tawesak Tanwandee (ORCID: https://orcid.org/0000-0001-7634-0843)
- Diana Payawal
- Jing Chen (ORCID: https://orcid.org/0000-0001-5972-3623)
- Guiqiang Wang (ORCID: https://orcid.org/0000-0002-0317-7536)
- George K.K. Lau (ORCID: https://orcid.org/0000-0002-8928-3769)
- Wenhong Zhang (ORCID: https://orcid.org/0000-0002-1246-0747)
- Hui Zhuang
Institutions
- Aga Khan University (PK)
- Siriraj Hospital (TH)
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- Capital Medical University (CN)
- Peking University (CN)
- Fudan University (CN)
- Mahidol University (TH)
- José Rizal University (PH)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Humanity & Health (CN)
- University of Yamanashi Hospital (JP)
- Institute of Liver and Biliary Sciences (IN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Peking University First Hospital (CN)
- Peking University International Hospital (CN)
- Beijing Friendship Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Hepatology International
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1007/s12072-024-10744-9
- Citations
- 5
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.77